Switching to Fixed-Dose Bictegravir, Emtricitabine, and Tenofovir Alafenamide (B/F/TAF) in Virologically Suppressed HIV-1 Infected Women: A Randomized, Open-Label, Multicenter, Active-Controlled, Phase 3, Noninferiority Trial

• Main Authors: Cissy Kityo, Debbie Hagins, Ellen Koenig, Anchalee Avihingsanon, Ploenchan Chetchotisakd, Khuanchai Supparatpinyo, Natalya Gankina, Vadim Pokrovsky, Evgeny Voronin, Jeffrey L. Stephens, Edwin Dejesus, Hui Wang, Rima K. Acosta, Huyen Cao, Erin Quirk, Hal Martin, Tariro Makadzange
• Format: Journal
• Published: 2020
• Subjects: Medicine
• Online Access: https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85073178758&origin=inward; http://cmuir.cmu.ac.th/jspui/handle/6653943832/67951
• Institution: Chiang Mai University

© 2019 Wolters Kluwer Health, Inc. All rights reserved. Background:Bictegravir, coformulated with emtricitabine/tenofovir alafenamide as a fixed-dose combination (B/F/TAF), is recommended for treatment of HIV-1-infection. Multiple studies of B/F/TAF in treatment-naive and virologically suppressed co...